Shots:
- The company has received CE mark in EU and approval in Australia for its new EnSite X EP system which offers the option to navigate the cardiac anatomy in two different ways on one platform.
- The system can create a 3D model of the patient’s cardiac anatomy in real time and will enable physicians to spot areas of the heart that need ablation treatment. The system is currently pending 510(k) clearance from the US FDA
- Additionally, the company has received the US FDA & CE mark approval for the EnSite LiveView Dynamic Display, which allows data from the Advisor HD Grid mapping catheter, Sensor Enabled to be visualized in real-time during cardiac ablation procedures
Click here to read the full press release/ article | Ref: Abbott | Image: PCR News
The post Abbott to Launch its Cardiac Mapping Platform in Europe and Australia first appeared on PharmaShots.
